Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valrubicin Maintenance in Bladder CIS
NCT01310803Phase 3Terminated
- Sponsor
- Endo International plc
- Start
- May 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valrubicin in carcinoma in situ of the bladder (CIS) (2 arms), sponsored by Endo International plc. Primary endpoint: Efficacy of Maintenance Therapy (Time to Event) at 2 years. Started May 2011; status: terminated.
02
Drugs
valrubicin
03
Conditions
carcinoma in situ of the bladder (CIS)
Beyond the preview
Go deeper on NCT01310803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310803.